Both agents are more potent in vitro than current protease inhibitors and are active against HIV-1 strains resistant to indinavir, nelfinavir, and amprenavir. DuPont is currently working on daily and twice-daily formulations of these drugs. PRO 140 is a monoclonal antibody to CCR5 that blocks HIV-1 entry but doesn't interfere with CCR5 activity. This combination merits further study in humans. In assessing trough drug levels in relation to the C min for isolates from patients who failed efavirenz, DPC961 was superior to DPC083.
Further study is ongoing.
Most of the rashes were mild-moderate in severity. The Johns Hopkins University on behalf of its Division of Infectious Diseases and AIDS Service. All rights reserved. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained in this site because no single reference or service can take the place of medical training, education, and experience. Consumers are cautioned that this site is not intended to provide medical advice about any specific medical condition they may have or treatment they may need and they are encouraged to call or see their physician or other health care provider promptly with any health related questions they may have.